Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor

Background: Aberrant activation of RAS-RAF-MEK-ERK signaling pathway has been implicated in more than one-third of all malignancies. MEK inhibitors are promising therapeutic approaches to target this signaling pathway. Though four MEK inhibitors have been approved by FDA, these compounds possess eit...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Yahong Liu, Ying Cheng, Gongchao Huang, Xiangying Xia, Xingkai Wang, Hongqi Tian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Subjects:	mek inhibitor RAF/RAS mutant cancer tunlametinib drug combination high potency
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1271268/full